Alcami, a contract development and manufacturing organisation (CDMO), announced on Tuesday that it has completed Phase II of its cGMP biostorage facility situated in Amherst, New Hampshire.
The company's 104,000 square feet area is now completely operational and supports various cGMP storage requirements. The whole site covers a total area of 160,000 square feet.
The company is planning to complete phase III in the first quarter of 2023 and will add an additional 56,000 square feet of new capacity.
BioArctic reports EMA acceptance of MAA for lecanemab in early Alzheimer's disease
Sanofi and Regeneron's Dupilumab recommended for expanded EU approval
Genetesis Makes New Appointments to Executive Leadership Team
Sling Therapeutics names new chief medical officer
Annovis Bio reveals patient enrolment update for Phase three buntanetap study
Brukinsa Approved in the US for Chronic Lymphocytic Leukemia